This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brown Fitzpatrick, S. Articles by Rosenstein, B. J. Search for Related Content PubMed PubMed Citation Articles by Brown Fitzpatrick, S. Articles by Rosenstein, B. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antibiotics Hazardous Substances DB TOBRAMYCIN Social Bookmarking                         What's this?

Moxalactam-tobramycin-resistant Pseudomonas aeruginosa Isolates in Patients with Cystic Fibrosis

Eudowood Pulmonary Division and Cystic Fibrosis Center, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

Beryl J. Rosenstein

Eudowood Pulmonary Division and Cystic Fibrosis Center, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

In vitro studies have shown synergistic killing activity against Pseudomonas aeruginosa (PA) with the combination of an aminoglycoside and moxalactam, a new beta-lactam agent. We describe three patients with cystic fibrosis (CF) with PA isolates that were resistant to all single-agent antibiotics, but sensitive to the combination of moxalactam-tobramycin. Initially, all patients had a good clinical response to this combination. However, during a second course of therapy, there was clinical deterioration coincident with the rapid emergence of moxalactam-tobramycin-resistant PA isolates.

Clinical Pediatrics, Vol. 22, No. 9, 628-630 (1983)
DOI: 10.1177/000992288302200907


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?